[Treatment of patients with chronic hepatitis C who never had been treated].
Service d'Hépatologie et de Gastroentérologie, Hôpital Henri-Mondor, Université Paris XII, AP-HP, 51 avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil.
Christophe
C
Hézode
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D001835:Body Weight; D004796:Clinical Enzyme Tests; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000209:etiology / Q000473:pathology; D015201:Meta-Analysis as Topic; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D000637:Transaminases / Q000097:blood; D019562:Viral Load
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D010919:Placebos; D011994:Recombinant Proteins; D012254:Ribavirin; D007372:Interferons; D000637:Transaminases